













OCUGEN'S MISSION IS TO DEVELOP INNOVATIVE THERAPIES TO ADDRESS RARE AND UNDERSERVED EYE DISEASES

	Indication	Preclinical	Phase 1	Phase 2	Phase 3
MODIFIER GENE THERAPY PLATFORM					
OCU400 <i>NR2E3-AAV</i>	<i>NR2E3</i> Mutation-Associated Retinal Degeneration Orphan - US				
	Leber Congenital Amaurosis (LCA)				
	Bardet-Biedl Syndrome (BBS)				
	Rhodopsin Mutation- Associated Retinal Degeneration				
OCU410 <i>RORA-AAV</i>	Dry AMD				
RETINAL DISEASES					
OCU200 Tumstatin-Transferrin	Wet AMD				
	Diabetic Macular Edema				
	Diabetic Retinopathy				
OCU100 LEDGF 1-326	Retinitis Pigmentosa Orphan - US & EU				
OCULAR SURFACE DISEASES					
OCU300 Brimonidine 0.18% OcuNanoE™	oGVHD Orphan - US				
OCU310 Brimonidine 0.2% OcuNanoE™	Dry Eye Disease				

OCU300: oGVHD (brimonidine 0.18% nanoemulsion)

Proprietary nanoemulsion of brimonidine tartrate for the treatment of ocular redness and ocular discomfort in patients with ocular graft versus host disease (oGVHD)

- **Positive clinical data in 2 investigator-led Phase 1/2 studies:**
 - Showed beneficial effect in 89% of patients based on symptom endpoint (discomfort score)
 - Decrease in ocular redness score (sign) within and between treatment groups, $p < 0.05$
- **First patient dosed in US Phase 3 study: December 2018**
- **No approved treatment exists; first to market opportunity**
- **Only company awarded Orphan Designation by the FDA**

Ocular graft versus host disease (oGVHD)

- Common complication of allogeneic bone marrow transplant that occurs in ~60% of patients
- Driven by chronic autoimmune inflammation, causing severe ocular surface disease, visual impairment and significantly diminishes quality of life
- Symptoms often manifest as severe dry eye, delaying proper diagnosis and treatment
- Expected to affect ~63,000 patients in US by 2020

OCU310: Dry Eye Disease (brimonidine 0.2% nanoemulsion)

Proprietary nanoemulsion of brimonidine tartrate for the treatment of signs and symptoms of dry eye disease (DED)

- **Positive Phase 2 results: Randomized, multi-center, double-blinded, placebo-controlled study**
 - Statistically significant improvement ($p < 0.05$) in symptom endpoint
 - Near statistically significant improvement in sign endpoint
 - Met primary endpoint of tolerability over 12-week period
- **First US Phase 3 study fully enrolled in 7 weeks**

OcuNanoE - Ocugen's ONE Platform™

Nanoemulsion Formulation Enhances Treatment Effect

- Oil/water based product increases preferential ocular tissue distribution of the drug
- Designed to enhance tear film stability and provide symptom relief
- Preservative-Free

Modifier Gene Therapy Platform

- Novel gene therapy platform with potential to be broadly effective across a range of genetically diverse inherited degenerative retinal diseases (IRDs)
- Delivers one or more nuclear hormone receptor (NHR) genes directly to the retina
- Expression of NHRs within the retina resets the homeostasis and prevents a range of IRDs

OCU400: NR2E3 Mutation-Associated Retinal Degeneration (NR2E3-AAV)

Gene augmentation therapy product for treatment of NR2E3 mutation-associated retinal degeneration

- Orphan Drug Designation
- Expression of NR2E3 within the retina may help reset retinal homeostasis, stabilize cells and potentially rescue photoreceptor degeneration


Modifier Gene Therapy approach provides for treatment of multiple genotype retinal degenerative diseases, including orphan IRDs such as Leber Congenital Amaurosis (LCA), Bardet-Biedl Syndrome (BBS), Rhodopsin mutations associated retinitis pigmentosa and other retinal degenerations

OCU200: wet-AMD (transferrin-tumstatin)

Targeted fusion protein for wet age-related macular degeneration (wet-AMD)

- First company focused on macromolecule (fusion protein) to target integrins for ocular diseases
- Integrin-targeting based approaches are actively explored in a variety of disease treatments, such as cancer, autoimmune, angiogenic and fibrotic treatments
- Integrin ($\alpha V\beta 3$) targeting with tumstatin is unique and broadly inhibits ocular neovascularization
- Targeting component transferrin directs activity to sub-retinal choroidal epithelial cells, where wet-AMD first occurs
- In proof of concept studies, OCU200 demonstrated significantly better efficacy compared to anti-VEGF

Key Targeted Milestones



Seasoned Management Team

Shankar Musunuri, PhD, MBA
Chairman, CEO & Co-Founder

Dan Jorgensen, MD, MPH, MBA
Chief Medical Officer

Vijay Tammara, PhD
Vice President, Regulatory & Quality

Susan L. Drexler, MBA, CPA
Interim Chief Financial Officer &
Vice President, Business Development

Rasappa Arumugham, PhD
Chief Scientific Officer

Kelly Beck, MBA
Vice President, Investor Relations
& Administration